A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
Identifieur interne : 000D63 ( PubMed/Checkpoint ); précédent : 000D62; suivant : 000D64A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
Auteurs : Nicolas Sabarth [Autriche] ; Helga Savidis-Dacho ; Michael G. Schwendinger ; Peter Brühl ; Daniel Portsmouth ; Brian A. Crowe ; Otfried Kistner ; P Noel Barrett ; Thomas R. Kreil ; M Keith HowardSource :
- Vaccine [ 1873-2518 ] ; 2012.
Descripteurs français
- KwdFr :
- Animaux, Anticorps hétérophiles, Anticorps neutralisants, Calendrier vaccinal, Cellules Vero (virologie), Femelle, Immunité cellulaire (immunologie), Immunité humorale, Rappel de vaccin, Relation dose-réponse (immunologie), Réactions croisées (immunologie), Souris, Sous-type H5N1 du virus de la grippe A (immunologie), Sous-type H5N1 du virus de la grippe A (pathogénicité), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Immunité cellulaire, Réactions croisées, Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux.
- pathogénicité : Sous-type H5N1 du virus de la grippe A.
- virologie : Cellules Vero.
- Animaux, Anticorps hétérophiles, Anticorps neutralisants, Calendrier vaccinal, Femelle, Immunité humorale, Rappel de vaccin, Relation dose-réponse (immunologie), Souris.
English descriptors
- KwdEn :
- Animals, Antibodies, Heterophile, Antibodies, Neutralizing, Chlorocebus aethiops, Cross Reactions (immunology), Dose-Response Relationship, Immunologic, Female, Immunity, Cellular (immunology), Immunity, Humoral, Immunization Schedule, Immunization, Secondary, Influenza A Virus, H5N1 Subtype (immunology), Influenza A Virus, H5N1 Subtype (pathogenicity), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Mice, Vero Cells (virology).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , immunology : Influenza Vaccines.
- chemical : Antibodies, Heterophile, Antibodies, Neutralizing.
- immunology : Cross Reactions, Immunity, Cellular, Influenza A Virus, H5N1 Subtype.
- pathogenicity : Influenza A Virus, H5N1 Subtype.
- virology : Vero Cells.
- Animals, Chlorocebus aethiops, Dose-Response Relationship, Immunologic, Female, Immunity, Humoral, Immunization Schedule, Immunization, Secondary, Mice.
Abstract
Preparation for an H5N1 influenza pandemic in humans could include priming the population in the pre-pandemic period with a vaccine produced from an existing H5N1 vaccine strain, with the possibility of boosting with a pandemic virus vaccine when it becomes available. We investigated the longevity of the immune response after one or two priming immunizations with a whole-virus H5N1 vaccine and the extent to which this can be boosted by later immunization with either a homologous or heterologous vaccine.
DOI: 10.1016/j.vaccine.2012.06.043
PubMed: 22749797
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:22749797Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.</title><author><name sortKey="Sabarth, Nicolas" sort="Sabarth, Nicolas" uniqKey="Sabarth N" first="Nicolas" last="Sabarth">Nicolas Sabarth</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau</wicri:regionArea><wicri:noRegion>A-2304 Orth/Donau</wicri:noRegion></affiliation></author><author><name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name></author><author><name sortKey="Schwendinger, Michael G" sort="Schwendinger, Michael G" uniqKey="Schwendinger M" first="Michael G" last="Schwendinger">Michael G. Schwendinger</name></author><author><name sortKey="Bruhl, Peter" sort="Bruhl, Peter" uniqKey="Bruhl P" first="Peter" last="Brühl">Peter Brühl</name></author><author><name sortKey="Portsmouth, Daniel" sort="Portsmouth, Daniel" uniqKey="Portsmouth D" first="Daniel" last="Portsmouth">Daniel Portsmouth</name></author><author><name sortKey="Crowe, Brian A" sort="Crowe, Brian A" uniqKey="Crowe B" first="Brian A" last="Crowe">Brian A. Crowe</name></author><author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name></author><author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name></author><author><name sortKey="Kreil, Thomas R" sort="Kreil, Thomas R" uniqKey="Kreil T" first="Thomas R" last="Kreil">Thomas R. Kreil</name></author><author><name sortKey="Howard, M Keith" sort="Howard, M Keith" uniqKey="Howard M" first="M Keith" last="Howard">M Keith Howard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22749797</idno><idno type="pmid">22749797</idno><idno type="doi">10.1016/j.vaccine.2012.06.043</idno><idno type="wicri:Area/PubMed/Corpus">000C64</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C64</idno><idno type="wicri:Area/PubMed/Curation">000C64</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C64</idno><idno type="wicri:Area/PubMed/Checkpoint">000D63</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.</title><author><name sortKey="Sabarth, Nicolas" sort="Sabarth, Nicolas" uniqKey="Sabarth N" first="Nicolas" last="Sabarth">Nicolas Sabarth</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau</wicri:regionArea><wicri:noRegion>A-2304 Orth/Donau</wicri:noRegion></affiliation></author><author><name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name></author><author><name sortKey="Schwendinger, Michael G" sort="Schwendinger, Michael G" uniqKey="Schwendinger M" first="Michael G" last="Schwendinger">Michael G. Schwendinger</name></author><author><name sortKey="Bruhl, Peter" sort="Bruhl, Peter" uniqKey="Bruhl P" first="Peter" last="Brühl">Peter Brühl</name></author><author><name sortKey="Portsmouth, Daniel" sort="Portsmouth, Daniel" uniqKey="Portsmouth D" first="Daniel" last="Portsmouth">Daniel Portsmouth</name></author><author><name sortKey="Crowe, Brian A" sort="Crowe, Brian A" uniqKey="Crowe B" first="Brian A" last="Crowe">Brian A. Crowe</name></author><author><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name></author><author><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name></author><author><name sortKey="Kreil, Thomas R" sort="Kreil, Thomas R" uniqKey="Kreil T" first="Thomas R" last="Kreil">Thomas R. Kreil</name></author><author><name sortKey="Howard, M Keith" sort="Howard, M Keith" uniqKey="Howard M" first="M Keith" last="Howard">M Keith Howard</name></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Heterophile</term><term>Antibodies, Neutralizing</term><term>Chlorocebus aethiops</term><term>Cross Reactions (immunology)</term><term>Dose-Response Relationship, Immunologic</term><term>Female</term><term>Immunity, Cellular (immunology)</term><term>Immunity, Humoral</term><term>Immunization Schedule</term><term>Immunization, Secondary</term><term>Influenza A Virus, H5N1 Subtype (immunology)</term><term>Influenza A Virus, H5N1 Subtype (pathogenicity)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Mice</term><term>Vero Cells (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps hétérophiles</term><term>Anticorps neutralisants</term><term>Calendrier vaccinal</term><term>Cellules Vero (virologie)</term><term>Femelle</term><term>Immunité cellulaire (immunologie)</term><term>Immunité humorale</term><term>Rappel de vaccin</term><term>Relation dose-réponse (immunologie)</term><term>Réactions croisées (immunologie)</term><term>Souris</term><term>Sous-type H5N1 du virus de la grippe A (immunologie)</term><term>Sous-type H5N1 du virus de la grippe A (pathogénicité)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antibodies, Heterophile</term><term>Antibodies, Neutralizing</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Immunité cellulaire</term><term>Réactions croisées</term><term>Sous-type H5N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Cross Reactions</term><term>Immunity, Cellular</term><term>Influenza A Virus, H5N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cellules Vero</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Dose-Response Relationship, Immunologic</term><term>Female</term><term>Immunity, Humoral</term><term>Immunization Schedule</term><term>Immunization, Secondary</term><term>Mice</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Anticorps hétérophiles</term><term>Anticorps neutralisants</term><term>Calendrier vaccinal</term><term>Femelle</term><term>Immunité humorale</term><term>Rappel de vaccin</term><term>Relation dose-réponse (immunologie)</term><term>Souris</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Preparation for an H5N1 influenza pandemic in humans could include priming the population in the pre-pandemic period with a vaccine produced from an existing H5N1 vaccine strain, with the possibility of boosting with a pandemic virus vaccine when it becomes available. We investigated the longevity of the immune response after one or two priming immunizations with a whole-virus H5N1 vaccine and the extent to which this can be boosted by later immunization with either a homologous or heterologous vaccine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22749797</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>37</Issue><PubDate><Year>2012</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.</ArticleTitle><Pagination><MedlinePgn>5533-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2012.06.043</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Preparation for an H5N1 influenza pandemic in humans could include priming the population in the pre-pandemic period with a vaccine produced from an existing H5N1 vaccine strain, with the possibility of boosting with a pandemic virus vaccine when it becomes available. We investigated the longevity of the immune response after one or two priming immunizations with a whole-virus H5N1 vaccine and the extent to which this can be boosted by later immunization with either a homologous or heterologous vaccine.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Mice received one or two priming immunizations with a Vero cell culture-derived, whole-virus clade 1 H5N1 vaccine formulated to contain either 750 ng or 30 ng hemagglutinin. Six months after the first priming immunization, mice received either a booster immunization with the same clade 1 vaccine or a heterologous clade 2.1 vaccine, or buffer. Humoral and cellular immune responses were evaluated before and at regular intervals after immunizations. Three weeks after booster immunization, mice were challenged with a lethal dose of wild-type H5N1 virus from clades 1, 2.1 or 2.2 and survival was monitored for 14 days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One or two priming immunizations with the 750 ng or 30 ng HA formulations, respectively, induced H5N1-neutralizing antibody titers which were maintained for ≥ 6 months and provided long-term cross-clade protection against wild-type virus challenge. Both humoral and cellular immune responses were substantially increased by a booster immunization after 6 months. The broadest protective immunity was provided by an immunization regimen consisting of one or two priming immunizations with a clade 1 vaccine and a boosting immunization with a clade 2.1 vaccine.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data support the concept that pre-pandemic vaccination can provide robust and long-lasting H5N1 immunity which could be effectively boosted by immunization either with another pre-pandemic vaccine or with the pandemic strain vaccine.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sabarth</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savidis-Dacho</LastName><ForeName>Helga</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schwendinger</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Brühl</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Portsmouth</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Crowe</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Kistner</LastName><ForeName>Otfried</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>P Noel</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Kreil</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>M Keith</ForeName><Initials>MK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000910">Antibodies, Heterophile</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000910" MajorTopicYN="N">Antibodies, Heterophile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>01</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>06</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22749797</ArticleId><ArticleId IdType="pii">S0264-410X(12)00909-7</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2012.06.043</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Autriche</li></country></list><tree><noCountry><name sortKey="Barrett, P Noel" sort="Barrett, P Noel" uniqKey="Barrett P" first="P Noel" last="Barrett">P Noel Barrett</name><name sortKey="Bruhl, Peter" sort="Bruhl, Peter" uniqKey="Bruhl P" first="Peter" last="Brühl">Peter Brühl</name><name sortKey="Crowe, Brian A" sort="Crowe, Brian A" uniqKey="Crowe B" first="Brian A" last="Crowe">Brian A. Crowe</name><name sortKey="Howard, M Keith" sort="Howard, M Keith" uniqKey="Howard M" first="M Keith" last="Howard">M Keith Howard</name><name sortKey="Kistner, Otfried" sort="Kistner, Otfried" uniqKey="Kistner O" first="Otfried" last="Kistner">Otfried Kistner</name><name sortKey="Kreil, Thomas R" sort="Kreil, Thomas R" uniqKey="Kreil T" first="Thomas R" last="Kreil">Thomas R. Kreil</name><name sortKey="Portsmouth, Daniel" sort="Portsmouth, Daniel" uniqKey="Portsmouth D" first="Daniel" last="Portsmouth">Daniel Portsmouth</name><name sortKey="Savidis Dacho, Helga" sort="Savidis Dacho, Helga" uniqKey="Savidis Dacho H" first="Helga" last="Savidis-Dacho">Helga Savidis-Dacho</name><name sortKey="Schwendinger, Michael G" sort="Schwendinger, Michael G" uniqKey="Schwendinger M" first="Michael G" last="Schwendinger">Michael G. Schwendinger</name></noCountry><country name="Autriche"><noRegion><name sortKey="Sabarth, Nicolas" sort="Sabarth, Nicolas" uniqKey="Sabarth N" first="Nicolas" last="Sabarth">Nicolas Sabarth</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000D63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:22749797
|texte= A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:22749797" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |